Osiris Therapeutics, Inc.
OSIRIS THERAPEUTICS, INC. (Form: 8-K, Received: 05/31/2017 17:18:16)











Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): May 30, 2017




(Exact name of Registrant as specified in its charter)





(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)


7015 Albert Einstein Drive, Columbia, Maryland



(Address of principal executive offices)


(Zip Code)



Registrant’s telephone number, including area code: (443) 545-1800



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):


o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company o


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o





Item 5.02.                                         Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers


Appointment of Independent Director


On May 30, 2017, the Board appointed Mr. David White as an independent director. Mr. White will stand for re-election at the 2017 Annual Meeting of Stockholders.  Mr. White has been appointed to serve as a member of the Audit Committee.  Mr. White will be entitled to receive the compensation received by Board members under the Company’s standard compensation policy and practices.  There is no arrangement or understanding between Mr. White and any other person pursuant to which either was selected as a director. Mr. White does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.


A copy of the press release issued by the Company to announce the appointment of Mr. White to the Board is included as Exhibit 99.1 to this Current Report on Form 8-K.


Item 9.01                                            Financial Statements and Exhibits.


(d)  Exhibits


See Exhibit Index attached hereto.






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.















Linda Chang
Chief Financial Officer


Date: May 31, 2017




Exhibit Index


Exhibit No.





Press release, dated May 31, 2017



Exhibit 99.1



Osiris Appoints David White to its Board of Directors


COLUMBIA, Md. — May 31, 2017 - Osiris Therapeutics, Inc. (Pink Sheets: OSIR) is pleased to announce that its Board of Directors, at a Board Meeting on May 30 th , 2017, appointed Mr. David White as a director, upon recommendation of the Nominating Committee.  The Board of Directors also appointed Mr. White as a member of the Audit Committee.  Mr. White joins Osiris as an independent Board member and will stand for election at the Company’s 2017 Stockholders Meeting.


“We are pleased to have Mr. White join Osiris at this important time,” said Peter Friedli, Chairman of the Board. “David has extensive and highly relevant business and finance experience, and his contributions will be greatly appreciated.”


Mr. White has more than 25 years of corporate finance and public accounting experience with a track record of achievement in financial management, business and capital allocation strategy, and public company reporting, compliance and governance.  Most recently, Mr. White served as Senior Vice President, Chief Financial Officer and Treasurer of Choice Hotels, a New York Stock Exchange listed company, from 2007 until 2016. Prior to joining Choice Hotels in 2002, Mr. White held positions with Ernst & Young, Arthur Andersen and Statoil Energy.


About Osiris Therapeutics


Osiris Therapeutics, Inc., based in Columbia, Maryland, is a leader in researching, developing and marketing cellular regenerative medicine products that improve the health and lives of patients and lower overall healthcare costs.  Having developed the world’s first approved stem cell drug, Osiris works to further advance the medical field.  Osiris’ research and development in biotechnology focuses on innovation in regenerative medicine — including bioengineering, stem cell research and viable tissue based products.  Osiris has achieved commercial success with products in orthopaedics, sports medicine and wound care, including BIO , a viable bone matrix, Cartiform ® , a viable osteochondral allograft, Grafix ® , a cryopreserved placental membrane, and Stravix ® , a durable placental allograft.  Osiris, Grafix, Cartiform, and Stravix are trademarks of Osiris Therapeutics, Inc.  BIO 4  is a registered trademark of Howmedica Osteonics Corp.  More information can be found on the company’s website, www.osiris.com. (OSIR-G)


For additional information, please contact:


Diane Savoie

Osiris Therapeutics, Inc.

(443) 545-1839



7015 Albert Einstein Drive  ·   Columbia, Maryland  21046  · Ph 443.545.1800  ·   Fax 443.545.1701  ·   www.Osiris.com